NCT01837264View on ClinicalTrials.gov

Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

January 31, 2017

Conditions
Compartment Syndrome
Interventions
DEVICE

Magellan®

Trial Locations (1)

60453

Advocate Christ Medical Center, Oak Lawn

Sponsors

Lead Sponsor

Arteriocyte, Inc.
All Listed Sponsors
lead

Arteriocyte, Inc.

INDUSTRY

NCT01837264 - Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma | Biotech Hunter | Biotech Hunter